Lifecore Biomedical, Inc. (NASDAQ:LFCR) Position Boosted by Barclays PLC

Barclays PLC raised its holdings in shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR) by 301.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,944 shares of the company’s stock after acquiring an additional 22,489 shares during the quarter. Barclays PLC’s holdings in Lifecore Biomedical were worth $147,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Renaissance Technologies LLC bought a new stake in shares of Lifecore Biomedical in the 2nd quarter valued at approximately $56,000. Creative Planning bought a new stake in shares of Lifecore Biomedical in the 3rd quarter valued at approximately $69,000. Legion Partners Asset Management LLC grew its stake in shares of Lifecore Biomedical by 0.6% in the 2nd quarter. Legion Partners Asset Management LLC now owns 2,968,409 shares of the company’s stock valued at $15,228,000 after buying an additional 18,182 shares in the last quarter. Jane Street Group LLC grew its stake in shares of Lifecore Biomedical by 101.7% in the 3rd quarter. Jane Street Group LLC now owns 36,246 shares of the company’s stock valued at $179,000 after buying an additional 18,277 shares in the last quarter. Finally, 272 Capital LP grew its stake in shares of Lifecore Biomedical by 85.2% in the 3rd quarter. 272 Capital LP now owns 43,476 shares of the company’s stock valued at $214,000 after buying an additional 19,998 shares in the last quarter. Hedge funds and other institutional investors own 83.36% of the company’s stock.

Insider Activity at Lifecore Biomedical

In other Lifecore Biomedical news, CEO Paul Josephs purchased 17,000 shares of the company’s stock in a transaction dated Wednesday, January 8th. The shares were bought at an average price of $5.74 per share, with a total value of $97,580.00. Following the completion of the transaction, the chief executive officer now directly owns 559,717 shares in the company, valued at $3,212,775.58. This trade represents a 3.13 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 28.21% of the stock is owned by company insiders.

Analyst Ratings Changes

LFCR has been the subject of several analyst reports. Stephens restated an “equal weight” rating and issued a $6.00 target price on shares of Lifecore Biomedical in a report on Friday, January 3rd. Craig Hallum boosted their target price on Lifecore Biomedical from $8.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, November 22nd.

Lifecore Biomedical Stock Performance

Shares of NASDAQ:LFCR opened at $6.43 on Thursday. The business’s fifty day moving average price is $7.05 and its two-hundred day moving average price is $5.92. Lifecore Biomedical, Inc. has a fifty-two week low of $3.68 and a fifty-two week high of $8.90. The stock has a market capitalization of $238.10 million, a price-to-earnings ratio of -11.48 and a beta of 0.98. The company has a debt-to-equity ratio of 9.21, a current ratio of 2.32 and a quick ratio of 1.21.

Lifecore Biomedical (NASDAQ:LFCR) last announced its quarterly earnings results on Thursday, January 2nd. The company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.02. Lifecore Biomedical had a negative return on equity of 315.23% and a negative net margin of 12.52%. As a group, analysts predict that Lifecore Biomedical, Inc. will post -1 EPS for the current fiscal year.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.